Article
WuXi Biologics to Invest $389 Million in New Biomanufacturing Facility
Author(s):
The company will invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Ireland using single-use bioreactors.
On April 30, 2018, WuXi Biologics, part of WuXi AppTech, announced plans to invest EUR 325 million (US$389 million) in a new biomanufacturing facility in Mullagharlin, Dundalk, County Louth, Ireland.
According to the company, the new facility will use multiple single-use bioreactors for commercial biomanufacturing and is designed to be able to run continuous bioprocessing. A total of 48,000 L fed-batch and 6,000 L perfusion bioreactor capacity will also be installed.
The site will be on a 26-hectare campus and is the company’s first site outside of China. The investment is expected to create over 400 skilled jobs over a five-year span, as well as add approximately 700 construction jobs.
The project is supported by the Irish Government through IDA Ireland, an economic development body for Ireland.
Source: WuXi Biologics
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
